Isolated Polypeptide Binding Partners for Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and efficient means to detect and quantify antibodies against β-coronaviruses, such as SARS-CoV and SARS-CoV-2, in human samples, particularly for monitoring immune responses and predicting disease outcomes.
Innovation Solution
A method involving specific binding partners, including isolated polypeptides from the C-terminal domain of a nucleocapsid protein or the receptor binding domain of a spike protein, which bind to anti-β-coronavirus antibodies in samples, allowing for the detection and quantification of IgG and IgM antibodies, and determining the presence of neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect antibodies against β-coronaviruses, then detection can be performed, but the methods lack effectiveness and efficiency in accurately detecting and quantifying antibodies
Solution Approach 1:
The patent uses isolated polypeptides from the C-terminal domain of nucleocapsid protein or receptor binding domain of spike protein as intermediary binding partners. These intermediaries specifically bind to anti-β-coronavirus antibodies in the sample, enabling accurate detection and quantification through their specific antigen-antibody interactions, thereby improving both measurement precision and detection efficiency
2Measurement precision
If specific binding partners are used to detect anti-β-coronavirus antibodies, then detection accuracy is improved, but the complexity of the detection system increases
Solution Approach 1:
The patent extracts and uses only the critical functional domains (C-terminal domain of nucleocapsid protein or receptor binding domain of spike protein) as isolated polypeptides. This extraction approach maintains high detection accuracy by preserving the essential antigenic determinants while simplifying the overall system by eliminating unnecessary components of the viral structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables accurate detection and quantification of anti-SARS-CoV-2 antibodies, correlating with neutralizing activity and predicting disease outcomes, aiding in vaccine administration and monitoring immune status.
Implementation Method 1
specific binding partners, including isolated polypeptides from the C-terminal domain of a nucleocapsid protein or the receptor binding domain of a spike protein, which bind to anti-β-coronavirus antibodies in samples
Data Source
AI summary
Disclosed herein are methods, kits, systems, algorithms and improvements for detecting the presence of or determining an amount, quantity, concentration and/or level of an antibody against at least one type of β-coronavirus, such as, for example, an antibody against SARS-CoV or SARS-CoV-2, in one or more samples obtained from a subject. In some aspects, the methods, kits and systems relate to detecting the presence of or determining an amount, quantity, concentration and/or level of at least one type of anti-β-coronavirus antibody, such as an IgG and/or IgM antibody, in one or more samples obtained from a subject. The methods, kits systems, algorithms and improvements can also be used to monitor a subject's response and/or treatment to a β-coronavirus, determine whether or not a subject will develop or experience a cytokine storm, predict outcome in a subject, determine whether a subject can be administered a vaccine for a β-coronavirus, monitoring antibody response in individuals that have received a β-coronavirus vaccine (such as a SARS-CoV-2 vaccine), and/or determine the immune status of a subject.